{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:04:05Z","timestamp":1772805845480,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T00:00:00Z","timestamp":1383955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2490-13-58","type":"journal-article","created":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T06:02:48Z","timestamp":1383976968000},"source":"Crossref","is-referenced-by-count":34,"title":["Treatment patterns and characteristics of European patients with castration-resistant prostate cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"Cora N","family":"Sternberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwina S","family":"Baskin-Bey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Worsfold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,9]]},"reference":[{"key":"287_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2009.12.014","volume":"46","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010, 46: 765-781. 10.1016\/j.ejca.2009.12.014.","journal-title":"Eur J Cancer"},{"key":"287_CR2","unstructured":"CancerStats Prostate Cancer Incidence Statistics. http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/prostate\/incidence\/uk-prostate-cancer-incidence-statistics . Accessed Oct 2012"},{"key":"287_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1349-7006.2010.01774.x","volume":"102","author":"H Akaza","year":"2011","unstructured":"Akaza H: Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci. 2011, 102: 51-56. 10.1111\/j.1349-7006.2010.01774.x.","journal-title":"Cancer Sci"},{"key":"287_CR4","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, Van der Kwast TH, Wiegel T, Zattoni F: EAU guidelines on prostate cancer. http:\/\/www.uroweb.org\/gls\/pdf\/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf . Accessed Oct 2012"},{"key":"287_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","volume":"59","author":"N Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, der KT V, Wiegel T, Zattoni F, et al: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011, 59: 572-583. 10.1016\/j.eururo.2011.01.025.","journal-title":"Eur Urol"},{"issue":"Suppl 7","key":"287_CR6","doi-asserted-by":"crossref","first-page":"vii79","DOI":"10.1093\/annonc\/mdn477","volume":"19","author":"B Seruga","year":"2008","unstructured":"Seruga B, Tannock IF: The changing face of hormonal therapy for prostate cancer. Ann Oncol. 2008, 19 (Suppl 7): vii79-vii85.","journal-title":"Ann Oncol"},{"key":"287_CR7","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J: Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008, 24: 3063-3072. 10.1185\/03007990802457040.","journal-title":"Curr Med Res Opin"},{"key":"287_CR8","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00520-009-0617-3","volume":"17","author":"A Bredart","year":"2009","unstructured":"Bredart A, Dolbeault S, Savignoni A, Simard S, Gomme S, Asselain B, Copel L: Pilot evaluation of a French interdisciplinary supportive care department. Support Care Cancer. 2009, 17: 1507-1516. 10.1007\/s00520-009-0617-3.","journal-title":"Support Care Cancer"},{"key":"287_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/01.ju.0000106190.32540.6c","volume":"171","author":"S Kojima","year":"2004","unstructured":"Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H: Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol. 2004, 171: 679-683. 10.1097\/01.ju.0000106190.32540.6c.","journal-title":"J Urol"},{"key":"287_CR10","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.juro.2010.10.055","volume":"185","author":"N Lawrentschuk","year":"2011","unstructured":"Lawrentschuk N, Fernandes K, Bell D, Barkin J, Fleshner N: Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol. 2011, 185: 848-854. 10.1016\/j.juro.2010.10.055.","journal-title":"J Urol"},{"key":"287_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0090-4295(99)80182-4","volume":"46","author":"HI Scher","year":"1995","unstructured":"Scher HI, Steineck G, Kelly WK: Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995, 46: 142-148. 10.1016\/S0090-4295(99)80182-4.","journal-title":"Urology"},{"key":"287_CR12","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.juro.2006.06.071","volume":"176","author":"EJ Small","year":"2006","unstructured":"Small EJ, Ryan CJ: The case for secondary hormonal therapies in the chemotherapy age. J Urol. 2006, 176: S66-S71. 10.1016\/j.juro.2006.06.071.","journal-title":"J Urol"},{"key":"287_CR13","first-page":"34","volume":"2","author":"CN Sternberg","year":"2011","unstructured":"Sternberg CN, Fizazi K: The relevance of continued medical castration for patients with castration-resistant prostate cancer. AoU. 2011, 2: 34-39.","journal-title":"AoU"},{"key":"287_CR14","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/j.1464-410X.2008.07590.x","volume":"101","author":"J Anderson","year":"2008","unstructured":"Anderson J, Abrahamsson PA, Crawford D, Miller K, Tombal B: Management of advanced prostate cancer: can we improve on androgen deprivation therapy?. BJU Int. 2008, 101: 1497-1501. 10.1111\/j.1464-410X.2008.07590.x.","journal-title":"BJU Int"},{"key":"287_CR15","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.1988.6.9.1456","volume":"6","author":"A Manni","year":"1988","unstructured":"Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon R, et al: Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol. 1988, 6: 1456-1466.","journal-title":"J Clin Oncol"},{"key":"287_CR16","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1200\/JCO.1993.11.11.2167","volume":"11","author":"CD Taylor","year":"1993","unstructured":"Taylor CD, Elson P, Trump DL: Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993, 11: 2167-2172.","journal-title":"J Clin Oncol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2490-13-58\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-13-58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-13-58","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-13-58.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T16:49:57Z","timestamp":1596818997000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/1471-2490-13-58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,9]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["287"],"URL":"https:\/\/doi.org\/10.1186\/1471-2490-13-58","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,9]]},"article-number":"58"}}